Update! Note dates!
$Aslan Pharmaceuticals(ASLN.US$ Anticipated upcoming milestones
•Late breaking poster presentation of positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of COPD at the American Thoracic Society International Conference 2024 on May 20, 2024 •Topline interim data from the farudodstat Phase 2a study in AA expected in Q3 2024•Topline data from the TREK-DX trial of eblasakimab expected at the end of 2024•Selection of a development partner to advance eblasakimab into Phase 3 testing in AD and other indications
First quarter 2024 financial highlights
•Cash used in operations for the first quarter of 2024 was $7.4 million compared to $19.3 million for the same period in 2023. The decrease was due to lower clinical development and manufacturing costs for eblasakimab studies following the TREK-AD topline data readout in July 2023.•Research and development expenses were $5.9 million for the first quarter of 2024 compared to $14.1 million for the first quarter of 2023. The decrease was due to lower clinical development and manufacturing costs for eblasakimab studies following the TREK-AD topline data readout.•General and administrative expenses were $3.4 million for the first quarter of 2024 compared to $4.0 million for the first quarter of 2023. •Net loss attributable to stockholders for the first quarter of 2024 was $9.9 million compared to a net loss of $19.1 million for the first quarter of 2023.•As of March 31, 2024, the Company had cash and cash equivalents of $18.4 million.
•Late breaking poster presentation of positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of COPD at the American Thoracic Society International Conference 2024 on May 20, 2024 •Topline interim data from the farudodstat Phase 2a study in AA expected in Q3 2024•Topline data from the TREK-DX trial of eblasakimab expected at the end of 2024•Selection of a development partner to advance eblasakimab into Phase 3 testing in AD and other indications
First quarter 2024 financial highlights
•Cash used in operations for the first quarter of 2024 was $7.4 million compared to $19.3 million for the same period in 2023. The decrease was due to lower clinical development and manufacturing costs for eblasakimab studies following the TREK-AD topline data readout in July 2023.•Research and development expenses were $5.9 million for the first quarter of 2024 compared to $14.1 million for the first quarter of 2023. The decrease was due to lower clinical development and manufacturing costs for eblasakimab studies following the TREK-AD topline data readout.•General and administrative expenses were $3.4 million for the first quarter of 2024 compared to $4.0 million for the first quarter of 2023. •Net loss attributable to stockholders for the first quarter of 2024 was $9.9 million compared to a net loss of $19.1 million for the first quarter of 2023.•As of March 31, 2024, the Company had cash and cash equivalents of $18.4 million.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Papanice : Let's reap the joint stock
Trytosaveabit OP Papanice : I good with that! Hehehe. GL![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Papanice Trytosaveabit OP : Why is that? Aren't joint stocks bad? The number of shares is low
Trytosaveabit OP Papanice : Well since we are from different places I guess I need to ask for what you mean by “ joint stock “? Just to be sure I’m understanding so I can answer
Papanice Trytosaveabit OP : oh sorry is r s
Trytosaveabit OP Papanice : Yes there is a reverse split coming! I will be looking for a possible price increase before! And then after the R/S there is a few possible catalysts coming that could have it see a decent price increase after as well. JMO but overall I like it. NFA GL
Papanice : Looks like I'll have to cut it out first lol